Search Results for Turing

Showing 1 – 7

Senate to Take on Pharmaceutical Prices Again: Real Reform or More of the Same? By Zachary Brennan - Published 12 June 2017

The Senate Health, Education, Labor & Pensions (HELP) committee is holding a hearing Tuesday on prescription drug costs and will look to address how the drug delivery system affects what patients pay.

Categories: News, US, FDA, Crisis management, Drugs, Government affairs

Tags: Senate HELP, Mylan, Valeant, Turing, drug prices

Senators Look to Halt Price Spikes of Off-Patent Drugs By Zachary Brennan - Published 21 December 2016

Sens. Susan Collins (R-ME) and Claire McCaskill (D-MO) on Wednesday released a 131-page report explaining the details behind specific price increases for off-patent drugs and ways Congress can combat such spikes.

Categories: News, US, FDA, Crisis management, Drugs, Government affairs, Reimbursement

Tags: Valeant, Turing, Rodelis, Retrophin, Syprine, Cuprimine

Senators Slam Execs of Shkreli's Former Company Over Arbitrary Price Hike on Lifesaving Drug By Zachary Brennan - Published 17 March 2016

The Senate’s Special Committee on Aging held its second hearing on pharmaceutical pricing on Thursday, this time taking shots at executives of Martin Shkreli’s former company Turing Pharmaceuticals, which only exists because of a monopoly and 5,000% price hike on a toxoplasmosis drug first approved more than 50 years ago.

Categories: News, US, Crisis management, Drugs, Reimbursement, Research and development

Tags: Martin Shkreli, Turing, Retrophin, Kalobios, Senate Aging Committee

House Hearing Focuses on Harm Done by Drug Price Spikes By Zachary Brennan - Published 04 February 2016

The highly anticipated House Oversight Committee hearing on Thursday was not without its fireworks, though beyond the airing of a lot of discontent, few new options for halting drug price increases were brought to the table.

Categories: News, US, FDA, Drugs, Ethics, Government affairs, Reimbursement

Tags: Shkreli, Oversight hearing, Turing Pharmaceuticals, Valeant Pharmaceuticals

Senate Committee Considers Priority Reviews to Stem the Tide of Off-Patent Drug Price Hikes By Zachary Brennan - Published 09 December 2015

Sens. Susan Collins (R-Maine) and Claire McCaskill (D-Mo.) hosted a hearing Wednesday to discuss steep price increases for off-patent drugs and what can be done to ensure patients and hospitals can afford these drugs moving forward.

Categories: News, US, FDA, FTC, Crisis management, Drugs, Ethics, Government affairs, Manufacturing, Reimbursement

Tags: drug pricing, Martin Shkreli, Turing, Daraprim, off patent drug prices, Senate committee

GPhA: Congress Needs to Work With FDA to Increase Generic Competition By Zachary Brennan - Published 03 November 2015

The Generic Pharmaceutical Association (GPhA) has offered three key recommendations to Congress on how to work with the US Food and Drug Administration (FDA) to increase generic competition, according to a new report issued Tuesday.

Categories: News, US, FDA, Compliance, Distribution, Generic drugs, Prescription drugs, Government affairs, Manufacturing, Quality, Regulatory intelligence

Tags: generic drugs, GPhA, ANDAs, Generic Drug User Fee Amendments of 2012, user fees, Turing Pharmaceuticals

Clinton Urges FDA, FTC to Take Action Against Drug Price Hikes By Zachary Brennan - Published 19 October 2015

In two letters sent Monday, Democratic presidential hopeful Hillary Clinton called on the US Federal Trade Commission (FTC) and US Food and Drug Administration (FDA) to take action against pharmaceutical companies that inflate drug prices and keep generics off the market.

Categories: News, US, FDA, FTC, Distribution, Drugs, Government affairs, Manufacturing, Regulatory strategy

Tags: FTC, FDA, Ostroff, Hillary Clinton, Daraprim, Turing Pharmaceuticals